Objective: Knowledge of variation in thyroid function is important for interpretation of thyroid function tests. We aimed to describe intra-individual variation in thyroid function in patients with stable, untreated subclinical hypothyroidism (SCH) compared to euthyroid individuals to assess the importance of monitoring SCH patients. Design: We measured thyrotropin (TSH), free thyroxine (fT 4 ), and free triiodothyronine (fT 3 ) monthly for 1 year in a longitudinal study of 15 untreated SCH patients with initial TSH 5-12 mU=L, without trends in TSH, and compared findings with results from 15 euthyroid individuals. Main outcome: CV% was 17.0, 6.1, and 6.2 for TSH, fT 4 , and fT 3 , respectively. Overall CV% for TSH was lower in SCH patients than controls. Contrary to euthyroid individuals, CV% in SCH patients increased with rising mean TSH (r 2 ¼ 0.29, p ¼ 0.04). Individual disease set points were established with 45, 6, and 6 tests for TSH, fT 4 , and fT 3 , with 95% confidence. Differences required between two test results were 40%, 15%, and 15%, respectively, with 90% confidence. Conclusion: Percent variation in TSH was lower in SCH than in euthyroid controls, but increased with higher mean TSH. The number of tests needed to establish disease set points was high. The difference required between two tests to be truly different was 40% for TSH and 15% for fT 4 and fT 3 .
Introduction
V ariation in thyroid function tests is important because it influences the reliability of reference ranges and the interpretation of test results (1) . Variation in thyroid function tests was described in euthyroid individuals, which allowed for an estimate of the reliability of population-based reference ranges (2) (3) (4) (5) (6) (7) . Also, this provided new insight into the entity subclinical thyroid disease (6) .
Subclinical hypothyroidism (SCH) is a state with elevated serum thyrotropin (TSH) and an estimate of serum thyroxine (T 4 ) within reference limits of the assay. SCH is frequent in most population studied (8) (9) (10) (11) . The risk of progression to overt thyroid failure varied between studies, but thyroid function was stable in the majority of SCH patients in all studies (12) (13) (14) (15) (16) .
Alterations in thyroid function tests in patients with SCH may be part of normal changes in thyroid function or be caused by a further decline in thyroid function. In patients with stable SCH, alterations in thyroid function tests originate from individual biological variation around a diseasespecific set point. This variation may consist of individual biological variation as seen in healthy individuals (1) and possibly added variation attributable to fluctuations in thyroid disease activity. The variation in thyroid function tests in SCH may differ from that observed in the euthyroid state, and thus alter the conditions for interpretation of thyroid function tests in SCH (1) .
Knowledge of variation in thyroid function tests in SCH may improve the validity of interpretation of these tests, which is important for monitoring development of further thyroid failure in patients with SCH. However, no information is available on variation in thyroid function tests in patients with stable SCH.
We collected longitudinal data in a group of individuals with different degrees of SCH and identified a subgroup of patients with no trend in TSH over time. Data from these patients were used to describe the intra-individual variation in thyroid function tests in the SCH state and to calculate the number of tests needed to identify the individual level of thyroid dysfunction and the difference required for two test results to be significantly different in SCH.
Materials and Methods
Patients were referred to our department after finding SCH based on TSH at their family physician and included if TSH was between 5 and 12 mU=L and total T 4 was within the Department of Endocrinology and Medicine, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark.
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laboratory reference range (60-140 nmol=L) at the initial measurement and on repeated testing after 3 months. Exclusion criteria were previous thyroid disease, change in any type of medication during the past 3 months, medication or disease with influence on the thyroid, and pregnancy within the past 12 months. Participants were 2 men and 19 women aged 27 to 78 years, all were white and lived in northern Jutland, Denmark, an area with previous mild iodine deficiency, now covered by the Danish iodine fortification program (17) .
Participants were recruited from May 2004 to July 2005, and investigated monthly for a year from inclusion date to abolish potential seasonal effects. All investigational sessions, but one, were performed by the same investigator ( JK).
After an overnight fast, blood samples were drawn between 0900 and 1200 hours, following supine position for 30 minutes using minimal tourniquet. Serum was separated and stored at À208C until analysis.
All hormone measurements of the study samples were performed in duplicate in random order in a single batch with an Electro-ChemiLuminescence ImmunoAssay method on Modular Analytics E170 (Roche, Mannheim, Germany). Assay characteristics given by the manufacturer were (detection limit, reference range, single determination intraassay CV%): fT 4 , 0.3 pmol=L, 12-22 pmol=L, 1.8%; total T 4 , 5.4 nmol=L, 60-140 nmol=L (laboratory reference range), 1.6%; fT 3 , 0.4 pmol=L, 3.1-6.8 pmol=L, 1.7%. For TSH the detection limit and reference range were 0.005 mU=L and 0.27-4.2 mU=L; single determination intra-assay CV was 3.0% in samples with a mean TSH of 0.04 mU=L, 1.2% in samples with a mean TSH of 0.96 mU=L, and 1.1% in samples with a mean TSH of 9.37 mU=L. Thyroid peroxidase antibodies (TPOAb) were measured using anti-TPOn KRYPTOR (BRAHMS, Henningsdorf, Germany) with analytical sensitivity of 10 U=mL, intra-assay CV% 4.2, and interassay CV% 9.7, as stated by the manufacturer.
A total of 21 subclinically hypothyroid patients were included in the follow-up. One patient had a mean serum TSH of 3.3 mU=L over the subsequent 13 monthly samplings, one became overtly hypothyroid with steep increase in TSH and started levothyroxine treatment, and four patients had a significant trend in TSH during the study. Trend was defined as a statistically significant slope in TSH with time using linear regression. These six patients were excluded from the analyses. The remaining 15 patients had no trend in TSH and a mean TSH during the study period ranging from 4.4 to 12.3 mU=L.
Data from a group of 15 healthy men described in detail previously (6, 18) were included for comparison. In brief, they were aged 24-52 (median 38) years; lived in Randers, Jutland, Denmark; had a mean TSH of 1.27 (range 0.67-2.42) mU=L; mean total T 4 106 (range 81-137) nmol=L; and none were TPOAb positive.
Ethical approval by the Regional Ethics Committee in North-Jutland and Viborg County, Denmark, was obtained before the beginning of the study. All participants gave written informed consent.
Statistics and computations
Conformity to normal distribution of data in individuals was tested using Shapiro-Wilks test and inspection of Q-Q plots. The two groups were only limited skewed and nontransformed data were used for calculations as recommended (19) .
Coefficients of variation (CV) were calculated as the standard deviation (SD) divided by the mean and expressed 
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as percentages. Mann-Whitney test was used for comparison between the groups. Linear regression analysis was done with measures of variation (SD and CV) as response variables and mean values of TSH, fT 4 , and fT 3 as explanatory variables.
The patients varied around a set point for their individual disease state. The number of samples needed to establish this disease set point was calculated using the formula recommended for use when estimating the number of specimens required in biochemical measures: n ¼ (ZÂCV total =D) 2 (19) . Z was the number of standard deviations set to define the confidence interval (CI); i.e., Z ¼ 1.96 for a 95% CI. CV total included CV preanalytical , CV analytical , and CV biological , thus CV total was equal to the measured CV in our data. Median CV total was used for calculations. D was percent closeness to homeostatic set point; i.e., the precision level.
The difference required for two test results to be significantly different was calculated from: ZÂCV total Â2
1=2 according to recommendations (20) . Again, Z was confidence interval; i.e., Z ¼ 1.65 for 90% CI and 1.96 for 95% CI.
A p value of < 0.05 was considered significant. Table 1 . (6) .
Results
Among the SCH patients TSH followed a normal distribution in all but two patients (number 1 and 6). FT 4 and fT 3 were normally distributed in all but two (patients 5 and 15). In the group of healthy euthyroid subjects, all variables followed the normal distribution. SD of individual serum TSH ranged from 0.3 to 4.7 mU=L with mean SD 1.7 and median SD 1.1 mU=L. CV total ranged from 6% to 36% with a median and interquartile range (IQR, which is the 25th-75th percentile range) of 17% (13-21%). SD increased with increasing mean TSH levels (linear regression, p < 0.001) as did variation corrected for mean value (CV%) (linear regression, p ¼ 0.04). R 2 from regression of TSH mean and SD was 0.66 compared to 0.29 for TSH mean and CV%. In the euthyroid individuals median SD of TSH was 0.29 mU=L (IQR 0.20-0.36 mU=L) whereas median (IQR) of CV total was 23% (18-28%). CV total for TSH was lower in the SCH patients compared to the euthyroid individuals (MannWhitney, p ¼ 0.03), but there was no change in CV with changing mean TSH in the euthyroid individuals, as can be read from Fig. 2 .
Variation in thyroid function test in stable SCH patients
SD ranged from 0.36 to 1.24 pmol=L for fT 4 and from 0.12 to 0.43 pmol=L for fT 3 , and did not increase with increasing mean values (linear regression, fT 4 , p ¼ 0.65; fT 3 , p ¼ 0.45). Median CV total for fT 4 and fT 3 was 6.1% and 6.2% with IQR of 5.2-7.4% and 4.5-7.4%, respectively. Table 2 shows the number of samples needed to assess the disease-specific set point for TSH, fT 4 , and fT 3 for different precision levels in patients with stable SCH. A median of 12 (IQR, 7-26) samples were needed in SCH patients to be 95% confident of disease set point for serum TSH with a 90% precision level, while a precision level of 80% required a median of three (IQR, 2-6) samples. The number of samples needed for fT 4 or fT 3 disease-specific set point was lower. For fT 4 or fT 3 , two samples established the individual disease set point with a 90% precision and a 95% significance level. Figure 3 shows the probability of a significant change in test results with increasing relative differences between two specimens of TSH and of fT 4 or fT 3 . A lower CV% shifts the curve to the left whereas a higher CV% shifts the curve to the right; the IQR is shown for TSH. To be 90% confident of a significant difference requires a median 40% difference between two TSH tests and 15% difference between two tests of fT 4 or fT 3 .
Tools for monitoring SCH patients

Discussion
Variation in TSH secretion from the pituitary gland is generated by the hypothalamic circadian and pulsatile Variation was similar for fT 4 and fT 3 , as was the number of samples needed. Number of samples needed to estimate disease-specific set point was calculated as n ¼ (ZÂCV total =D) 2 . Z refers to number of standard deviations required for a confidence interval (CI), i.e., Z ¼ 1.96 for a 95% CI. CV total was the measured CV in our data. D is percent closeness to disease set point, i.e., the precision level (19) . TSH, thyrotropin; fT 4 , free thyroxine; fT 3 , free triiodothyronine.
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stimulation (suprapituitary stimulation) and modulated by the powerful negative feedback of thyroid hormones. Failure of the thyroid gland decreases the negative feedback and thereby increases the influence of unoccupied thyroid hormone receptors on both the suprapituitary and on the pituitary synthesis and secretion of TSH. We studied a cohort of patients with untreated SCH without a significant trend in TSH during a year. These patients displayed higher standard deviations (absolute variation) in TSH compared to euthyroid individuals. On the other hand, the relative variation (standard deviations relative to mean values, CV%) was lower in the SCH patients. Both the absolute and the relative variation in TSH were higher with higher mean TSH in the SCH patients. This was in contrast to the euthyroid individuals where no difference in the variation was seen with rising mean TSH.
It could be speculated that this progressive increase in the relative variation of TSH with more pronounced thyroid failure in stable SCH is caused by either a higher variation of hypothalamic signalling or an increased sensitivity of the thyrotropes in the pituitary gland and an increased production capacity for TSH related to lower levels of thyroid hormones. The fall in relative circadian variation in TSH in thyroid failure (21) favors the latter rather than the former mechanism. Another mechanism that could add to the increasing variation in the SCH state is that patients with more pronounced thyroid failure and higher TSH have higher variation in disease activity between months.
While variation in TSH was higher with higher mean TSH, variations in T 3 and T 4 were independent of mean values. This diversity in variation between TSH and thyroid hormones is consistent with different secretion mechanisms from the pituitary and the thyroid gland (22) (23) (24) .
The majority of our screened patients had stable SCH, in accordance with the findings in a number of previous studies (12) (13) (14) (15) (16) . In such patients, thyroid function tests vary around a disease-specific set point. This disease set point was established with 95% confidence with six monthly fT 4 and fT 3 tests, while six monthly measurements established TSH disease set point with 86% confidence. For TSH, two to three tests described the disease set point with around 80% confidence, while 95% confidence required 45 samplings. A large number of samples may be achieved through repeated sampling in subjects suspected of developing SCH, but is cumbersome and will hardly prove valuable in general use.
Progression of SCH to overt hypothyroidism is an important issue. The overall risk of progression to overt hypothyroidism has been settled in population studies (25) while the issue is more tricky in the individual patient. To guide evaluation we found that a 40% difference was required between two test results to indicate a true difference for TSH in the range between 4.4 and 12 mU=L. Due to more narrow variation in fT 4 and fT 3 , the difference required for similar changes in fT 4 and fT 3 was approximately 15%.
We used the longitudinal design. This allows a description of the intra-individual variation in the individual participants in the SCH state, where the between-individual variation is determined by the selection of participants. Thus, the cross-sectional design should not be used in the study of variation in thyroid function in SCH patients.
The euthyroid individuals used for comparison were all men, while the majority of SCH patients were women. However, as no difference was found between genders in variation in thyroid function tests in previous studies (1,23) we were confident with the comparisons. Our calculations did not include between-batch analytical variations. This would increase variation slightly, but is limited compared to the large biological variation (1), and would not alter the conclusions.
In conclusion, the relative variation in TSH was lower in SCH than in the euthyroid individuals used for comparison. Variation in TSH increased with increasing thyroid failure, while variation in thyroid hormones was unaltered in these patients with stable SCH with TSH initially up to 12 mU=L, as judged by monthly samplings during 1 year. Furthermore, for TSH levels below 12 mU=L, a second TSH had to be at least 40% different from a previous test to suggest a difference with 90% confidence. Similarly, fT 4 and fT 3 had to differ by 15% to denote a significant difference. FIG. 3 . The probability of a statistically significant change in test results is shown on the y-axis, with relative differences between two specimens of thyrotropin (TSH) and of free thyroxine (fT 4 ) or free triiodothyronine (fT 3 ) shown on the x-axis. fT 4 and fT 3 displayed similar variation and consequently had similar probability of a significant change between two tests (circles). For TSH, results using 1st and 3rd quartile of CV total (dotted lines) as well as median CV total (solid line triangles) are shown. The probability of significant change between two test results was calculated from: relative difference between two test ¼ ZÂCV total Â2 1=2 , were Z denotes the confidence interval, i.e., Z ¼ 1.96 for 95% CI (20) .
